We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| ALX Oncology Holdings Inc | NASDAQ:ALXO | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.77 | 11.22% | 17.55 | 17.05 | 17.60 | 17.825 | 15.47 | 15.68 | 950,245 | 01:00:00 |
From May 2022 to May 2024
By Dean Seal
ALX Oncology Holdings Inc. said the Food and Drug Administration granted orphan-drug designation to its drug evorpacept as a treatment for acute myeloid leukemia.
Sophia Randolph, the clinical-stage immuno-oncology company's chief medical officer, said Wednesday that the designation reflects the regulator's recognition that evorpacept has shown potential for improving the clinical outcomes of patients with advanced cancers.
Earlier this year, the company said that the FDA had given orphan-drug designation to evorpacept for the treatment of patients with gastric cancer and gastroesophageal junction cancer.
Orphan-drug designation is a special status given to drugs that show promise for potentially treating rare, or orphan, diseases that have fewer than 200,000 cases a year in the U.S.
Shares of ALX Oncology rose 24% to $10 in premarket trading.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
June 29, 2022 07:45 ET (11:45 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year ALX Oncology Chart |
1 Month ALX Oncology Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
